192 related articles for article (PubMed ID: 16651519)
1. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.
Wendel HG; de Stanchina E; Cepero E; Ray S; Emig M; Fridman JS; Veach DR; Bornmann WG; Clarkson B; McCombie WR; Kogan SC; Hochhaus A; Lowe SW
Proc Natl Acad Sci U S A; 2006 May; 103(19):7444-9. PubMed ID: 16651519
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
[TBL] [Abstract][Full Text] [Related]
3. The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
Williams RT; Sherr CJ
Adv Exp Med Biol; 2007; 604():107-14. PubMed ID: 17695724
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.
Weisberg E; Catley L; Wright RD; Moreno D; Banerji L; Ray A; Manley PW; Mestan J; Fabbro D; Jiang J; Hall-Meyers E; Callahan L; DellaGatta JL; Kung AL; Griffin JD
Blood; 2007 Mar; 109(5):2112-20. PubMed ID: 17068153
[TBL] [Abstract][Full Text] [Related]
5. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
8. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.
Roche-Lestienne C; Deluche L; Corm S; Tigaud I; Joha S; Philippe N; Geffroy S; Laï JL; Nicolini FE; Preudhomme C;
Blood; 2008 Apr; 111(7):3735-41. PubMed ID: 18202228
[TBL] [Abstract][Full Text] [Related]
9. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
Chandra J; Tracy J; Loegering D; Flatten K; Verstovsek S; Beran M; Gorre M; Estrov Z; Donato N; Talpaz M; Sawyers C; Bhalla K; Karp J; Sausville E; Kaufmann SH
Blood; 2006 Mar; 107(6):2501-6. PubMed ID: 16291594
[TBL] [Abstract][Full Text] [Related]
10. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
Lee J; Shen P; Zhang G; Wu X; Zhang X
Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
[TBL] [Abstract][Full Text] [Related]
11. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
[TBL] [Abstract][Full Text] [Related]
12. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
13. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.
Warmuth M; Simon N; Mitina O; Mathes R; Fabbro D; Manley PW; Buchdunger E; Forster K; Moarefi I; Hallek M
Blood; 2003 Jan; 101(2):664-72. PubMed ID: 12393636
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
Gontarewicz A; Balabanov S; Keller G; Colombo R; Graziano A; Pesenti E; Benten D; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
Blood; 2008 Apr; 111(8):4355-64. PubMed ID: 18268096
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.
Tipping AJ; Baluch S; Barnes DJ; Veach DR; Clarkson BM; Bornmann WG; Mahon FX; Goldman JM; Melo JV
Leukemia; 2004 Aug; 18(8):1352-6. PubMed ID: 15201856
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms and implications of imatinib resistance mutations in BCR-ABL.
Nardi V; Azam M; Daley GQ
Curr Opin Hematol; 2004 Jan; 11(1):35-43. PubMed ID: 14676625
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway.
Kurosu T; Wu N; Oshikawa G; Kagechika H; Miura O
Apoptosis; 2010 May; 15(5):608-20. PubMed ID: 20094798
[TBL] [Abstract][Full Text] [Related]
18. MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.
Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
Cancer Lett; 2015 Jan; 356(2 Pt B):597-605. PubMed ID: 25305453
[TBL] [Abstract][Full Text] [Related]
19. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.
Parmar S; Katsoulidis E; Verma A; Li Y; Sassano A; Lal L; Majchrzak B; Ravandi F; Tallman MS; Fish EN; Platanias LC
J Biol Chem; 2004 Jun; 279(24):25345-52. PubMed ID: 15056660
[TBL] [Abstract][Full Text] [Related]
20. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chu S; Holtz M; Gupta M; Bhatia R
Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
